# Assessment of Abuse Potential of Cebranopadol in Humans

> **NCT05256108** · PHASE1 · COMPLETED · sponsor: **Tris Pharma, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Human Abuse Potential

## Interventions

- **DRUG:** Oxycodone 40 mg
- **DRUG:** Tramadol 600 mg
- **DRUG:** Placebo
- **DRUG:** Cebranopadol 600 µg
- **DRUG:** Cebranopadol 1000 µg

## Key facts

- **NCT ID:** NCT05256108
- **Lead sponsor:** Tris Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256108, "Assessment of Abuse Potential of Cebranopadol in Humans". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05256108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*